Altimmune (NASDAQ:ALT) Upgraded at Wall Street Zen

Altimmune (NASDAQ:ALT - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Thursday.

ALT has been the subject of several other research reports. William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Altimmune currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.20.

Altimmune Stock Down 3.4%

Shares of Altimmune stock traded down $0.20 on Thursday, hitting $5.52. The stock had a trading volume of 1,369,484 shares, compared to its average volume of 2,413,502. Altimmune has a one year low of $3.55 and a one year high of $11.16. The stock's 50-day simple moving average is $5.11 and its two-hundred day simple moving average is $6.50. The stock has a market cap of $447.31 million, a price-to-earnings ratio of -3.57 and a beta of 1.13.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.09. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the prior year, the firm posted ($0.34) earnings per share. As a group, equities analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALT. GAMMA Investing LLC grew its position in shares of Altimmune by 214.2% in the 1st quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock worth $34,000 after buying an additional 4,598 shares during the period. SBI Securities Co. Ltd. bought a new stake in Altimmune during the fourth quarter worth about $45,000. Magnus Financial Group LLC purchased a new stake in Altimmune in the first quarter worth about $50,000. Headland Capital LLC bought a new position in shares of Altimmune during the first quarter valued at approximately $50,000. Finally, Geneos Wealth Management Inc. purchased a new position in shares of Altimmune during the first quarter valued at approximately $50,000. Hedge funds and other institutional investors own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.